CardiovascularFDA Approved

Angiotensin II (Giapreza)

Intravenous

Overview

A synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Angiotensin II acts on AT1 receptors on vascular smooth muscle to produce potent vasoconstriction, and on the adrenal cortex to stimulate aldosterone release.

Mechanism of Action

Exogenous administration raises blood pressure in vasodilatory shock refractory to conventional vasopressors by restoring vascular tone through a mechanism complementary to catecholamine vasopressors..

Research Summary & Key Findings

FDA-approved in 2017 as a vasopressor for adults with septic or other distributory shock. ATHOS-3 trial demonstrated significant blood pressure improvement (MAP increase of 12.5 mmHg vs. placebo) in patients with catecholamine-resistant vasodilatory shock (Khanna et al., NEJM, 2017). Post-hoc analyses suggest particular benefit in patients with elevated renin and those on renal replacement therapy.

Clinical Status

FDA Approved

Angiotensin II (Giapreza) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Angiotensin II (Giapreza) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Angiotensin II (Giapreza).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.